NCT00489086View on ClinicalTrials.gov

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Neoplastic Syndrome
Interventions
DRUG

tazarotene

Tazarotene is a member of the acetylenic class of retinoids.

Trial Locations (2)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York

94609

Children's Hospital and Research Center Oakland, Oakland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UCSF Benioff Children's Hospital Oakland

OTHER

NCT00489086 - Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face | Biotech Hunter | Biotech Hunter